PHARMACEUTICAL & BIOTECH EXPERIENCE MEDIMMUNE, GAITHERSBURG, MD - Full Time Employment Global Safety Officer/Medical Director, December 2009

- Present Acting Therapeutic Area Head: Oncology & Immunology (Multiple Oncology Biologics ) * Review and edit First Time in Humans (FTIH), Phase 1 through 3 clinical Protoc ols, Informed Consent Forms and Investigation Brochures with focus on safety. * Provide safety support regarding protocol design and changes/updates in clinic al trial protocols using monoclonal antibodies and immunogenic compounds that ta rget cellular pathways for the purpose of inhibiting/stopping the development of multiplication and metastasis of cancer cells. * Author the developmental Risk Management Plans (dRMP's) and other internal tec hnical documents for all Oncology compounds. * Oversee the medical assessment of Individual Case Safety Reports (ICSR's) and training of staff on this task. * Respond to regulatory agency (FDA, PMDA, Irish Medical Board, EMEA) inquiries for all phases of clinical trials and postmarketing products. * Serve on teams that develop toxicology studies, determine clinical trial indic ations and design the associated preclinical protocols with focus on safety matt ers * Review and edit documents prepared for publication (abstracts, posters, journa l articles, etc.) * Review and edit IMPDs (clinical section regarding safety and risk management) * Author Integrative Product Development Plans, in particular, the sections on D rug Safety and Risk Management for each Oncology investigational compound * Developed a method that allows intelligent forecasting of safety signals in on cology biologics, as well as other investigational and postmarketed compounds * Serve as an active participating member on the clinical and preclinical trial design teams for new investigational products * Serve as an active contributing member on the teams that assess and plan how t o manage dose limiting toxicities that occur in phase I through III clinical tri als Therapeutic Area: Infectious Disease & Allergy/Immunology (RSV Prophylaxis) Responsibilities include serving as the Patient Safety Lead on the MedImmune tea m that went before the FDA Advisory Committee. This assignment included * Worked closely with the Clinical, Regulatory, Research, Product Development an d Statistic team leaders in preparing for this meeting. * Assessed the safety profile of existing monoclonal antibodies, in particular S ynagis, and compared them to Motavizumab, the product under consideration for FD A approval for prophylactic treatment of RSV in compromised infants and toddlers . * Prepared questions and answers related to Safety concerns that could be, and w ere actually asked by the FDA advisory committee. * Prepared Safety slides for the presentation, as well as backup slides to be us ed during the FDA Advisory Committee meeting as visual aids to answer Safety-rel ated questions. * Trained with professional consultants, as a team, in preparation for respondin g to difficult questions/issues that could be addressed at the FDA meeting. Significant unique accomplishments consist of: * Serving as the Patient Safety Lead on the MedImmune team that went before the FDA Advisory Committee within a few months of joining this company. * Development of a process for intelligent prediction of safety signals that cou ld be caused by new compounds that are currently under consideration for FTIH cl inical trials. * Characterized Hypersensitivity that occurs with the use of monoclonal antibodi es * Oncology Expert for 7 Investigational Compounds at MedImmune in Patient Safety

ALLERGAN, Irvine, CA - Full Time Employment Global Safety Officer/Medical Director, March 2008 - September 2009 Therapeutic Area: Neurology & Ophthalmology Responsibilities include participation in all aspects of pharmacovigilance and r isk management activities for assigned products, both Postmarketed and in Early Development. This assignment includes * Overseeing all postmarketing safety issues as the Global Safety Officer for Al lergan products including Botox and Botox Cosmetic which have more than 20 indic ations in 80 countries, and other urologic and ophthalmic products. * Oversee safety issues as the Global Safety Officer for Early Development of Bo tox for new indications (Migraines, Hyperhidrosis, Pain Disorders) and Gatifloxa cin Ophthalmic (Neonates, High Dose) * Medical analysis and decision making regarding postmarketing safety matters in the development and maintenance of the Company Core (Safety) Data Sheet for eac h assigned product. * Performing ad hoc aggregate analysis and safety reports. * Responding to field alert reports. * Development and review of the Periodic Safety Update Reports (PSUR's) * Participation in the editing and review of the Risk Management Plans (RMP's) a nd Risk Evaluation and Mitigation Strategy (REMS) reports. * Medical assessment of Individual Case Safety Reports (ICSR's) and training of staff on this task. * Responding to regulatory agency inquiries. * Safety liaison to GSK Japan and China focusing on postmarketing safety includi ng responses to regulatory agencies, as part of Allergan's commitment through a Safety Data Exchange Agreement (SDEA) for Botox. Significant unique accomplishments consist of: * Development of a new signal detection automated system using the PRR dispropor tionality signal detection method to monitor unusual adverse events for all Alle rgan products. * Designing and development of an improved standardized method for performing me dical analyses on each product so that comparisons on safety issues from year-to -year can easily be done between products without compromising individual result s. * Restructuring of the itinerary for running the Global Safety Officer biweekly morning reports in which safety concerns are discussed for each product. * Improvement of working relationships between R&D clinical teams and the postma rketing safety group. * Improvement of the format used in medically assessing each individual case saf ety report (ICSR) in order that this information can be transferred directly int o the Periodic Safety Update Reports (PSUR's) as needed. * During a transitional period of six months, functioned as the only full-time G lobal Safety Officer in the United States without missing any deadlines. * Received an Excellence Award for Botox Analysis that ruled out any relationshi p between the use of this product and the development of QT Prolongation. * Received an Excellence Award for development of a Signal Detection Program for the company. ABBOTT VASCULAR, Santa Clara, CA - Consulting Assignment Medical Consultant and Writer, November 2007 - February 2008 Therapeutic Area: Cardiology Responsibilities include writing and editing reports and documents on Drug-eluti ng Stent research and clinical trials. * Primary author of Interventional Cardiology book chapter on cardiovascular ste nts (i) beginning with review of coronary artery disease (CAD), (ii) Signs/sympt oms of CAD, history and development of cardiovascular stents, (iii) risks versus benefits of using CV stents, (iv) discussion on the different types of drug-elu ding stents, (v) introduction on state-of-the-art CV stents including newer desi

gns of Drug-eluting stents and Biodegradable stents * Provided a comprehensive outline of publicized Cardiovascular Stent Clinical T rials for review and inclusion in Interventional Cardiology Text THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA Postdoctorate Fellow, July 2002 - February 2005 Therapeutic Area: Oncology & Immunology Responsibilities in Oncology included the development of Indirect Immunofluoresc ence Protocol for analyzing epithelial cancer cells detected in peripheral blood to be observed by a new diagnostic tool invented by a team of engineers and sci entists from the Palo Alto Research Center. Planning pre-clinical trial experime nts for testing stage 4 breast cancer patients that have detectable cancer cells in peripheral blood. Investigating several potential biomarkers to be used in t he above protocol in terms of their metastatic value and cancer cell types. Resp onsibilities in the Microbiology and Immunology Department included evaluating g ene targets for Anthrax and other aggressive bacterial exposure due to bioterror ism. - Major accomplishment in Oncology included setting up a new cancer research lab within one year of clinical study; and in Microbiology and Immunology, the identificati on of gene targets that could be blocked and prevent infection and harm to human s when exposed to Anthrax and other like aggressive bacteria. BIOTECH EXECUTIVE NETWORK CONSULTANTS, Los Angeles CA - Consulting Assignment Senior Partner and Practice Leader, November 2001 - July 2002 Area of Expertise: Biotech Business Development Primary responsibilities included business development in the establishment of n ew clients, especially in the Healthcare and High Technology Industries. - Major accomplishments included assisting executives of small companies in developing ideas and protocols for new products, as well as recruit the right people to hel p them get the job done. CLINICAL EXPERIENCE MOBILE PHYSICIAN SERVICES/HOME PHYSICIANS MEDICAL GROUP, San Diego, CA Primary Care Physician, July 2006 - Present (Part time during employment with A llergan & MedImmune) Therapeutic Area: Internal Medicine Serve as the primary care physician of "house-bound" patients who cannot be tran sported into a clinic setting for medical care. These patients are adults who ar e seriously ill, physically handicapped, or both, and therefore, require medical services in at their place of residence. - Major accomplishment is cost savings to Medicare and other insurance plans by treating and stabilizing patients who would otherwise have to be ambulance-transported and treated in a hospital/emerg ency room setting. ARMENIA GOSPEL MISSION AND WORLD VISION INTERNATIONAL, Country of Armenia - Cons ulting Assignment Medical Director, July 2001 - October 2001 Area of Expertise: Healthcare Diplomat and Physician Advisor Primary responsibilities included teaming up with Armenia Gospel Mission and Wor ld Vision International to do a complete healthcare assessment of Armenia for th e purpose of determining if Armenia qualified for third world status, and theref ore, was eligible for support from World Vision International. This process req uired * Developing and performing a national study to identify the immediate medical n eeds of children and the elderly by interviewing several doctors and missionarie s before traveling to this country. * Meeting with the Heads of State, Surgeon General, Directors of World Vision, a nd several other leaders in Armenia to discuss their healthcare concerns and way s the US could privately assist in meeting those needs. * Propose methods to improve healthcare in Armenia with the help of World Vision

International and Armenian Gospel Mission. Major accomplishment included the establishment of World Vision International in the country of Armenia by providing complete documentation including proposals for how each organization can best assist in meeting the medical needs in Armeni a. A seventy page document was presented to both organizations with proposals re garding how to improve the healthcare in Armenia, as well as ways to raise funds within Armenia to cover this cost. Many of the proposals have been implemented and are in process today. MEDICAL CLINIC PRACTICE, Los Angeles County, CA Primary Care Physician, May 1995 - July 2001 Therapeutic Area: General Practice Primary responsibilities included patient care and building a practice. - Major accomplishments included (i) the development of financial and human resource st rategies for increasing business and profits from business start-up to $500,000 in two years, (ii ) performed Clinical Study on Micronized Plant-based Progeste rone and the effects on sleep patterns in Women, and (iii) lectured on women's h ealth issues and treatment protocols for managing endocrine-related medical diso rders, and obesity. HEALTHCARE RESOURCE GROUP, Whittier, CA Medical Director and Consultant, May 1998 - July 2001 (Full-time to Part-time As signments) Area of Expertise: Primary Care Medicine Primary responsibilities included the professional focus on clinical care issues ; in particular * Developing integrative health protocols for a number of disease processes. * Researched and authored disease management protocols for health care facilitie s. * Leading team to transition a Native American Indian reservation hospital from a US Government operated facility to a privately operated hospital * Developed cost effective Medical Protocols for outpatient patient treatment pr ograms affiliated with the hospital. * Designed an electronic cardiac device. Major accomplishment included all the above responsibilities. NONTECHNICAL BUSINESS EXPERIENCE AMABILESTRINGS.COM, San Diego, CA Founder of this company & Composer, August 2004 - Present (Part-time); February 2005 - June 2006 (Full-time) AmabileStrings.com is a small business founded for the purpose of raising money to fund orphanages in third world countries that provide a home environment for children who would otherwise be on the streets without any parental guidance. T he source of income is from music composed by me, and possibly other composers, which is then licensed to orchestras and film companies for performance or film scores. This has been a part-time business, except for February 2005 through Ju ne 2006. - Major accomplishments included (i) setting up a small business, (ii) writing business plans, (iii) understanding and developing budgets and expense reports, and (iv) fundraising.

ENGINEERING & PHYSICS PROFESSIONAL EXPERIENCE PARSONS CORPORATION, Pasadena, CA Senior Technical Management Consultant, August 1998 - February 1999 Under U.S. Government sponsorship lead the team that assessed the safety and ope ration of a new Chemical Weapons Destruction Facility (CWDF) to be built in coop

eration with the Russian Federation in Russia. Primary responsibilities included (i) serving as a systems coordinator for the CWDF for both engineering and mana gement, (ii) developing the system description for this facility and performed S afety Analysis checks on plant design, (iii) participating in technical meetings with the lead Russian scientists in Moscow, Russia regarding business and engin eering issues, (iv) recommending design modifications to significantly improve t he human and environmental safety of the facility, and (v) educating executive m anagement regarding system operations and health concerns involving the plant de sign. Major accomplishments included system description for chemical weapons des truction facility in Russia and identifying major health and safety concerns in building and operating this facility and ways to reduce the safety concerns. IBM CORPORATION, Burlington, VT Senior Member of Technical Staff/Manager, April 1980 - March 1988 Primary responsibilities included the assessment of IBM's ability to perform Sem iconductor Failure Analysis (SCFA) on semiconductor computer chips after mass ma nufacturing of these devices. Researching new technologies to support the implem entation of a SCFA program over five years. Major accomplishments included (i) D eveloped a patent on a direct memory access controller that communicated with a network of microprocessors. (ii) Designed 32-bit semiconductor memory chips for large-frame computer systems. (iii) Authored a corporate report on the role of S CFA within the IBM Corporation. (iv) Developed an enterprise-wide study to deter mine IBM's ability to adequately perform SCFA at all IBM facilities once a produ ct has been mass reproduced. (v) Designed and taught advanced applied semiconduc tor device physics courses to professional IBM engineers. (vi) Designed and taug ht courses on the assessment of computer semiconductor device mathematical model s used in the CAD system to simulate the operation and function of semiconductor computer chips. (vi) Taught professional IBM engineers how to develop and impro ve current CAD modeling techniques and (vii) taught professional IBM engineers h ow to research and develop new ideas related to computer device design. AT&T LABORATORIES, Holmdel, NJ Senior Member of Technical Staff, July 1977 - April 1980 Responsibilities included assisting in the design and development of fiber optic digital and analog timing circuits to be used for telecommunication transmissio ns. Developed a high-speed analog amplifier for signal enhancement along the fib er optic cable. Research Team Member working on the development of one of the fi rst 32-bit microprocessors to be used in telecommunications. Major accomplishmen t included lecturing to technical and management staff on the implementation of the direct memory access controller into the 32-bit microprocessor system. PROFESSIONAL SOCIETIES American Medical Association, 1988 - present Institute of Electronic and Electrical Engineering, 1980 - late 1990's GRANTS Recipient of NIH Scholarship (2003-2005) AWARDS/ HONORS Math Honors Society Physics Honors Society Engineering Honors Society Honors in Medical School: Psychiatry, Oncology Medical Research, Clinical Diagno sis, Pediatrics, Family Practice, Cardiology Research SCIENTIFIC PUBLICATIONS 1. Kim, Ha, Lee, Stanton et al. (2007). Mutagenesis by Retroviral Insertion in C

hemical Mutagen-Generated Quasi-Haploid Mammalian Cells. BioTechniques. 2. Stanton, S. (2005). NIH Grant Proposal for Oncology Epithelial Cancer Marker s. 3. Kreig, A., Stanton, S., (1990). Self Study Program For Pathology. Penn Stat e University College of Medicine; an In-house publication for Medical Students s tudying for Pathology section of Medical Boards, part II. 4. Stanton, S. (1986). Semiconductor Device Physics and Device Modeling Lecture Series at IBM. 5. Stanton, S. (1982). 8N Computer System Direct Memory Access Controller. Uni ted States Patent Disclosure. 6. Stanton, S. (1981). Evaluation of Semiconductor Failure Analysis Within the I BM Corporation; Management and Research. IBM Confidential Corporate Publication . 7. Stanton, S., (1978). High Speed Digital Oscillators For Fiber Optic Signal T ransmission, Bell Telephone Laboratories Confidential Research Publication; Holm del, New Jersey. 8. Lord, Stanton, S., et al. (1978). Second Order Dipole Phenomena of Liquid Cr ystals At Low Temperatures. Journal of Theoretical Physics. PRESENTATIONS 1. Shingles-Diagnosis and Treatment, Sunrise LaCosta Senior Living Center 2008 2. Immunofluorescence of Epithelial Cancer Cells, The Scripps Research Institute 2004 3. Cytohesine 4, A Gene Target to Ward Off Anthrax Infections?, The Scripps Rese arch Institute 2004 4. Anthrax, The Medicine and Immunology Behind This Bacteria, The Scripps Resear ch Institute 2004 5. Hormone Imbalance in Women, Huntington Hospital, Pasadena, CA 1997 6. Obesity and Weight Loss, Huntington Hospital, Pasadena, CA 1997 7. Endocrinology for Women, Orange County, CA 1997 8. Taught a four-course series on the physics of computers, beginning with the b asic classical physics models through quantum physics and numerical analysis mod eling of semiconductor devices and computer architecture design. IBM, Essex Junc tion, VT 1982 - 1986 9. Presentation on a process for intelligent prediction of safety signals that c ould be caused by new compounds that are currently under consideration for FTIH clinical trials. MedImmune, Gaithersburg, MD. ACADEMIC BACKGROUND Post Doctorate Onc/Immunology The Scripps Research Institute, San Diego, CA (200 5) Residency LA County & USC Medical Center, Los Angeles, CA (1995) M.D. Penn State University-College of Medicine, Hershey, PA (1993) MSEE Cornell University, Ithaca, New York (1978)

BS in Electrical Engr. & BS in Physics Drexel University, Philadelphia, PA (1977 )